Paxilitaxel induces apoptosis accompanied by protective autophagy in osteosarcoma cells through hypoxia‑inducible factor‑1α pathway

Guo,Yuanqing; Huang,Chuangxin; Li,Guowei; Chen,Tao; Li,Jinxiang; Huang,Zongwen

doi:10.3892/mmr.2015.3860

Paxilitaxel induces apoptosis accompanied by protective autophagy in osteosarcoma cells through hypoxia‑inducible factor‑1α pathway

Authors:
- Yuanqing Guo
- Chuangxin Huang
- Guowei Li
- Tao Chen
- Jinxiang Li
- Zongwen Huang
View Affiliations

Affiliations: Department of Orthopedics, The Fifth Affiliated Hospital of Sun Yat‑Sen University, Zhuhai, Guangdong 519000, P.R. China
Published online on: May 27, 2015 https://doi.org/10.3892/mmr.2015.3860
Pages: 3681-3687

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paxilitaxel, a drug used in cancer chemoprevention and treatment, has shown promising anti‑cancer effects against a broad spectrum of tumors. However, the effect of paxilitaxel on osteoblasts has remained to be elucidated. The aim of the present study was to investigate the anti‑tumor effect of paxilitaxel on human osteosarcoma cancer cells, the underlying molecular mechanism as well as drug resistance involved. The results showed that paxilitaxel not only induced apoptosis via the mitochondrial pathway but also induced autophagy, which partially inhibited cell apoptosis. The present study also demonstrated that paxilitaxel induced autophagy through the hypoxia‑inducible factor (HIF)‑1α pathway. Moreover, paxilitaxel‑induced apoptosis decreased following incubation with with the autophagy inducer rapamycin. By contrast, co‑treatment with the HIF‑1α inhibitor YC‑1 or autophagy inhibitor 3‑methyladenine significantly blocked autophagy and augmented the anti‑tumor effects of paxilitaxel. Therefore, the results of the present study suggested that the combination of paxilitaxel with an autophagy inhibitor or a HIF‑1α inhibitor may be an effective and potent strategy for improved chemotherapy of osteosarcoma in the future.

View Figures

View References

1	Markiewicz K, Zeman K, Kozar A and Gołebiowska-Wawrzyniak M: Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis-preliminary report. Med Wieku Rozwoj. 15:25–31. 2011.In Polish. PubMed/NCBI
2	Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M and Santana VM: Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer. 117:2770–2778. 2011. View Article : Google Scholar : PubMed/NCBI
3	DeRegis CJ, Moore AS, Rand WM and Berg J: Cisplatin and doxorubicin toxicosis in dogs with osteosarcoma. J Vet Intern Med. 17:668–673. 2003. View Article : Google Scholar : PubMed/NCBI
4	Moore-Maxwell CA, Datto MB and Hulette CM: Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol. 17:241–247. 2004. View Article : Google Scholar : PubMed/NCBI
5	Yoneyama K, Konishi H, Yahata T, Fujita K, Aoki Y, Doi D, Matsushima T, Kodama S, Honma S, Kato H, Nakayama H, et al: A Phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic cancer network trial. J Nippon Med Sch. 81:28–34. 2014. View Article : Google Scholar : PubMed/NCBI
6	Von Hoff DD, Goldstein D and Renschler MF: Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med. 370:479–480. 2014.PubMed/NCBI
7	Dank M, Budi L, Piko B, Mangel L, Erfan J, Cseh J, Ruzsa A and Landherr L: First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: Results from the AVAREG study. Anticancer Res. 34:1275–1280. 2014.PubMed/NCBI
8	Orvedahl A, Sumpter R Jr, Xiao G, Ng A, Zou Z, Tang Y, Narimatsu M, Gilpin C, Sun Q, Roth M, Forst CV, et al: Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature. 480:113–117. 2011. View Article : Google Scholar : PubMed/NCBI
9	Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ and Thorburn A: Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 8:200–212. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nakamura O, Hitora T, Akisue T, Kawamoto T, Yamagami Y and Yamamoto T: Inhibition of induced autophagy increases apoptosis of Nara-H cells. Int J Oncol. 39:1545–1452. 2011.PubMed/NCBI
11	Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A and Kögel D: Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with BH3 mimetic (−)-Gossypol (AT-101). BMC Cancer. 15:2242015. View Article : Google Scholar
12	Monti E and Gariboldi MB: HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol. 4:62–77. 2011. View Article : Google Scholar
13	Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, et al: Phosphorylated ERalpha, HIF-1alpha and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 27:227–234. 2009. View Article : Google Scholar
14	Zhao Y, Chen G, Zhang W, Xu N, Zhu JY, Jia J, Sun ZJ, Wang YN and Zhao YF: Autophagy regulates hypoxia-induced osteoclastogenesis through the HIF-1α/BNIP3 signaling pathway. Cell Physiol. 227:639–648. 2012. View Article : Google Scholar
15	Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ and Semenza GL: Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. Biol Chem. 283:10892–10903. 2008. View Article : Google Scholar
16	Wessel D and Flügge UI: A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 138:141–143. 1984. View Article : Google Scholar : PubMed/NCBI
17	Adesida AB, Grady LM, Khan WS, Millward-Sadler SJ, Salter DM and Hardingham TE: Human meniscus cells express hypoxia inducible factor-1α and increased SOX9 in response to low oxygen tension in cell aggregate culture. Arthritis Res Ther. 9:R692007. View Article : Google Scholar
18	Zeng Y, Yang X, Wang J, Fan J, Kong Q and Yu X: Aristolochic acid I induced autophagy extenuates cell apoptosis via ERK 1/2 pathway in renal tubular epithelial cells. PLoS One. 7:e303122012. View Article : Google Scholar : PubMed/NCBI
19	Amarnath S, Flomerfelt FA, Costanzo CM, Foley JE, Mariotti J, Konecki DM, Gangopadhyay A, Eckhaus M, Wong S, Levine BL, June CH and Fowler DH: Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy. 6:523–541. 2010. View Article : Google Scholar : PubMed/NCBI
20	Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ and Xu YH: Anti-tumor effect of betapaxilitaxel in glioblastoma cells depends on p38 MAPK activation. Cancer Lett. 264:127–134. 2008. View Article : Google Scholar : PubMed/NCBI
21	Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E and Li QQ: Antitumor effect of betapaxilitaxel in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci. 62:881–893. 2005. View Article : Google Scholar : PubMed/NCBI
22	Guo B, Yang M, Liang D, Yang L, Cao J and Zhang L: Cell apoptosis induced by zinc deficiency in osteoblastic MC3T3-E1 cells via a mitochondrial-mediated pathway. Mol Cell Biochem. 361:209–216. 2012. View Article : Google Scholar
23	Rasul A, Yu B, Yang LF, Ali M, Khan M, Ma T and Yang H: Induction of mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells by kuraridin and Nor-kurarinone isolated from Sophora flavescens. Asian Pac J Cancer Prev. 12:2499–2504. 2011.
24	Granell S and Baldini G: Inclusion bodies and autophagosomes: are ER-derived protective organelles different than classical autophagosomes? Autophagy. 4:375–377. 2008. View Article : Google Scholar : PubMed/NCBI
25	Deretic V, Delgado M, Vergne I, Master S, De Haro S, Ponpuak M and Singh S: Autophagy in immunity against mycobacterium tuberculosis: a model system to dissect immunological roles of autophagy. Curr Top Microbiol Immunol. 335:169–188. 2009.PubMed/NCBI
26	Hofius D, Munch D, Bressendorff S, Mundy J and Petersen M: Role of autophagy in disease resistance and hypersensitive response-associated cell death. Cell Death Differ. 18:1257–1262. 2011. View Article : Google Scholar : PubMed/NCBI
27	Zhang T, Li Y, Park KA, Byun HS, Won M, Jeon J, Lee Y, Seok JH, Choi SW, Lee SH, Man Kim J, et al: Cucurbitacin induces autophagy through mitochondrial ROS production which counteracts to limit caspase-dependent apoptosis. Autophagy. 8:559–576. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ait-Mohamed O, Battisti V, Joliot V, Fritsch L, Pontis J, Medjkane S, Redeuilh C, Lamouri A, Fahy C, Rholam M, Atmani D and Ait-Si-Ali S: Acetonic extract of Buxus sempervirens induces cell cycle arrest, apoptosis and autophagy in breast cancer cells. PLoS One. 6:e245372011. View Article : Google Scholar : PubMed/NCBI
29	Lu HH, Kao SY, Liu TY, Liu ST, Huang WP, Chang KW and Lin SC: Areca nut extract induced oxidative stress and upregulated hypoxia inducing factor leading to autophagy in oral cancer cells. Autophagy. 6:725–737. 2010. View Article : Google Scholar : PubMed/NCBI
30	Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouysségur J and Mazure NM: Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 29:2570–2581. 2009. View Article : Google Scholar : PubMed/NCBI
31	Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Loze MT, Tang D and Cao L: DAMP-mediated autophagy contributes to drug resistance. Autophagy. 7:112–124. 2011. View Article : Google Scholar :
32	Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ and Cleveland JL: Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 110:313–322. 2007. View Article : Google Scholar : PubMed/NCBI
33	Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A: HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer. 12:42012. View Article : Google Scholar : PubMed/NCBI